Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.01
-0.00 (-33.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-1.2M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-518.7%
↓Gross Margin
47.3%
↓Debt/Equity
0.43
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.9%
FCF CAGR
—
FCF margin
-398.1%
FCF / Net income
0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $312285.0 · net income $-1.7M · FCF $-1.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $312285.00 | $312285.00 | $471414.00 | $288272.00 | $235449.00 |
| Net Income | $-1.7M | $-1.7M | $-1.1M | $-1.6M | $-1.5M |
| EBITDA | $-1.3M | $-1.3M | $-807925.00 | $-1.2M | $-811474.00 |
| EPS | — | — | — | -0.01 | -0.01 |
| Gross Margin | 47.3% | 47.3% | 34.9% | 29.2% | -7.5% |
| Operating Margin | -441.6% | -441.6% | -193.7% | -477.4% | -696.8% |
| Net Margin | -533.4% | -533.4% | -243.6% | -567.3% | -623.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.43 | 0.43 | 0.01 | 0.01 | 0.91 |
| Current Ratio | 0.62 | 0.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.2M | $-1.2M | $-796848.00 | $-1.4M | $-1.5M |
| Returns | |||||
| ROE | -518.7% | -518.7% | -137.6% | -84.0% | -100.0% |
| Valuation | |||||
| P/B | 14.73 | 14.73 | 7.17 | 2.82 | 2.88 |
| Growth & Yield | |||||
| Revenue Growth | -33.8% | -33.8% | 63.5% | 22.4% | — |
| EPS Growth | — | — | — | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.